PortalPublikationenEfficacy and Safety of an Everolimus- vs. a Mycophenolate Mo...

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients

Standard

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. / Brunkhorst, Lena Caroline; Fichtner, Alexander; Höcker, Britta; Burmeister, Greta; Ahlenstiel-Grunow, Thurid; Krupka, Kai; Bald, Martin; Zapf, Antonia; Tönshoff, Burkhard; Pape, Lars.

in: PLOS ONE, Jahrgang 10, Nr. 9, 2015, S. e0135439.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Brunkhorst, LC, Fichtner, A, Höcker, B, Burmeister, G, Ahlenstiel-Grunow, T, Krupka, K, Bald, M, Zapf, A, Tönshoff, B & Pape, L 2015, 'Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients', PLOS ONE, Jg. 10, Nr. 9, S. e0135439. https://doi.org/10.1371/journal.pone.0135439

APA

Brunkhorst, L. C., Fichtner, A., Höcker, B., Burmeister, G., Ahlenstiel-Grunow, T., Krupka, K., Bald, M., Zapf, A., Tönshoff, B., & Pape, L. (2015). Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. PLOS ONE, 10(9), e0135439. https://doi.org/10.1371/journal.pone.0135439

Vancouver

Brunkhorst LC, Fichtner A, Höcker B, Burmeister G, Ahlenstiel-Grunow T, Krupka K et al. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. PLOS ONE. 2015;10(9):e0135439. https://doi.org/10.1371/journal.pone.0135439

Bibtex

@article{4f4d66231bbc4dff80fa641dc8ee7765,
title = "Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients",
abstract = "INTRODUCTION: Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce.PATIENTS/METHODS: We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients on everolimus plus low-dose cyclosporine, who were matched (1:2) with a control group of 70 children receiving a standard-dose calcineurin-inhibitor- and mycophenolate mofetil-based regimen.RESULTS: Corticosteroids were withdrawn in 83% in the everolimus vs. 39% in the control group (p<0.001). Patient and graft survival were comparable. The rate of biopsy-proven acute rejection episodes Banff score ≥ IA during the first year post-transplant was 6% in the everolimus vs. 13% in the control group (p = 0.23). The rate of de novo donor-specific HLA antibodies (11% in everolimus, 18% in controls) was comparable (p = 0.55). At 4 years post-transplant, mean eGFR in the everolimus group was 56±33 ml/min per 1.73 m² vs. 63±22 ml/min per 1.73 m² in the control group (p = 0.14). Everolimus therapy was associated with less BK polyomavirus replication (3% vs. 17% in controls; p = 0.04), but with a higher percentage of arterial hypertension and more hyperlipidemia (p<0.001).CONCLUSION: In pediatric renal transplantation, an everolimus-based regimen with low-dose cyclosporine yields comparable four year results as a standard regimen, but with a different side effect profile.",
keywords = "Adolescent, Anti-Inflammatory Agents, Non-Steroidal, Biomarkers, Child, Child, Preschool, Cohort Studies, Drug Therapy, Combination, Everolimus, Female, Graft Rejection, Graft Survival, HLA Antigens, Hospitalization, Humans, Immunosuppressive Agents, Isoantibodies, Kidney Function Tests, Kidney Transplantation, Male, Mycophenolic Acid, Opportunistic Infections, Retrospective Studies, Tissue Donors, Transplant Recipients, Treatment Outcome, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Brunkhorst, {Lena Caroline} and Alexander Fichtner and Britta H{\"o}cker and Greta Burmeister and Thurid Ahlenstiel-Grunow and Kai Krupka and Martin Bald and Antonia Zapf and Burkhard T{\"o}nshoff and Lars Pape",
year = "2015",
doi = "10.1371/journal.pone.0135439",
language = "English",
volume = "10",
pages = "e0135439",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

RIS

TY - JOUR

T1 - Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients

AU - Brunkhorst, Lena Caroline

AU - Fichtner, Alexander

AU - Höcker, Britta

AU - Burmeister, Greta

AU - Ahlenstiel-Grunow, Thurid

AU - Krupka, Kai

AU - Bald, Martin

AU - Zapf, Antonia

AU - Tönshoff, Burkhard

AU - Pape, Lars

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce.PATIENTS/METHODS: We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients on everolimus plus low-dose cyclosporine, who were matched (1:2) with a control group of 70 children receiving a standard-dose calcineurin-inhibitor- and mycophenolate mofetil-based regimen.RESULTS: Corticosteroids were withdrawn in 83% in the everolimus vs. 39% in the control group (p<0.001). Patient and graft survival were comparable. The rate of biopsy-proven acute rejection episodes Banff score ≥ IA during the first year post-transplant was 6% in the everolimus vs. 13% in the control group (p = 0.23). The rate of de novo donor-specific HLA antibodies (11% in everolimus, 18% in controls) was comparable (p = 0.55). At 4 years post-transplant, mean eGFR in the everolimus group was 56±33 ml/min per 1.73 m² vs. 63±22 ml/min per 1.73 m² in the control group (p = 0.14). Everolimus therapy was associated with less BK polyomavirus replication (3% vs. 17% in controls; p = 0.04), but with a higher percentage of arterial hypertension and more hyperlipidemia (p<0.001).CONCLUSION: In pediatric renal transplantation, an everolimus-based regimen with low-dose cyclosporine yields comparable four year results as a standard regimen, but with a different side effect profile.

AB - INTRODUCTION: Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce.PATIENTS/METHODS: We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients on everolimus plus low-dose cyclosporine, who were matched (1:2) with a control group of 70 children receiving a standard-dose calcineurin-inhibitor- and mycophenolate mofetil-based regimen.RESULTS: Corticosteroids were withdrawn in 83% in the everolimus vs. 39% in the control group (p<0.001). Patient and graft survival were comparable. The rate of biopsy-proven acute rejection episodes Banff score ≥ IA during the first year post-transplant was 6% in the everolimus vs. 13% in the control group (p = 0.23). The rate of de novo donor-specific HLA antibodies (11% in everolimus, 18% in controls) was comparable (p = 0.55). At 4 years post-transplant, mean eGFR in the everolimus group was 56±33 ml/min per 1.73 m² vs. 63±22 ml/min per 1.73 m² in the control group (p = 0.14). Everolimus therapy was associated with less BK polyomavirus replication (3% vs. 17% in controls; p = 0.04), but with a higher percentage of arterial hypertension and more hyperlipidemia (p<0.001).CONCLUSION: In pediatric renal transplantation, an everolimus-based regimen with low-dose cyclosporine yields comparable four year results as a standard regimen, but with a different side effect profile.

KW - Adolescent

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Biomarkers

KW - Child

KW - Child, Preschool

KW - Cohort Studies

KW - Drug Therapy, Combination

KW - Everolimus

KW - Female

KW - Graft Rejection

KW - Graft Survival

KW - HLA Antigens

KW - Hospitalization

KW - Humans

KW - Immunosuppressive Agents

KW - Isoantibodies

KW - Kidney Function Tests

KW - Kidney Transplantation

KW - Male

KW - Mycophenolic Acid

KW - Opportunistic Infections

KW - Retrospective Studies

KW - Tissue Donors

KW - Transplant Recipients

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1371/journal.pone.0135439

DO - 10.1371/journal.pone.0135439

M3 - SCORING: Journal article

C2 - 26407177

VL - 10

SP - e0135439

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 9

ER -